On March 26, 2026, Dianthus Therapeutics, Inc. (the "Company") announced the posting of an updated corporate presentation on its investor relations website. This presentation includes significant updates regarding the Company’s clinical trials and regulatory interactions with the Food and Drug Administration (FDA). Notably, the Company proposed changes to the screening criteria and required routine labs for its claseprubart clinical trials, which are aimed at improving patient enrollment and safety assessments. The proposed changes include the removal of anti-nuclear antibodies (ANAs) as a screening criterion, which has been a common reason for screen failures across all three claseprubart programs. Additionally, the Company suggested the removal of routine ANA testing during clinical trials and the reclassification of the hypothetical risk of systemic lupus erythematosus (SLE) to drug-induced lupus (DIL). These proposals are based on patient experiences to date and scientific consensus from published data. The FDA has provided written feedback agreeing to all three proposals for ongoing and future trials, indicating a positive regulatory outlook for the Company. The presentation also highlights the Company’s strong financial position, with approximately $1.2 billion in cash, which is expected to fund operations into 2030. The Company is targeting significant milestones in 2026, including the initiation of Phase 3 trials for claseprubart and updates on indication prioritization for its other investigational product, DNTH212. Overall, these developments are expected to enhance the Company’s operational execution and strategic outlook, potentially leading to a noticeable positive effect on its stock price.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.